BackNuvation Bio Overview
Nuvation Bio Inc - Ordinary Shares - Class A

Nuvation Bio Target Price

Analysts' average 12-month price target for Nuvation Bio is $20.

Get informed when a big investor buys or sells

+ Follow

Share Price

$6.1

Average Target Price

$20.00227.9% upside

3 analysts in the last 4 months

High: $21 | Low: $19

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-07RBC CapitalLeonid Timashev$20227.9% upsideOpen
2026-07-27H.C. Wainwright$21244.3% upsideOpen
2026-07-07RBC Capital$19211.5% upsideOpen
2026-01-27Truist Financial$13113.1% upsideOpen
2026-01-21RBC CapitalLeonid Timashev$1296.7% upsideOpen
2026-01-12H.C. Wainwright$17178.7% upsideOpen
2026-01-07UBSMichael Yee$1063.9% upsideOpen
2025-12-11H.C. Wainwright$18195.1% upsideOpen
2025-12-01H.C. WainwrightRobert Burns$1063.9% upsideOpen
2025-11-24Truist Financial$1180.3% upsideOpen
2025-11-20JMP Securities$1063.9% upsideOpen
2025-11-04JMP Securities$831.1% upsideOpen
2025-04-23JMP SecuritiesSilvan Tuerkcan$61.6% downsideOpen
2024-09-16H.C. WainwrightRobert Burns$714.8% upsideOpen
2024-04-17RBC CapitalKennen MacKay$518% downsideOpen
2024-03-28H.C. WainwrightRobert Burns$831.1% upsideOpen
2024-03-27JefferiesMichael Yee$1063.9% upsideOpen
2024-03-26BTIGKaveri Pohlman$518% downsideOpen
2023-01-06Jefferies$267.2% downsideOpen
2022-05-04H.C. Wainwright$14129.5% upsideOpen

Nuvation Bio (NUVB) FAQ

Nuvation Bio's target price stands at $20. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $20 for NUVB implies 227.9% upside versus today's price ($6.1). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Nuvation Bio's target price evolved across reporting periods, while the comparison chart places NUVB next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Nuvation Bio's reading of $20 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.